Since 1993, the AACR has awarded more than $540 million in grants to fund meritorious research projects across the spectrum of cancer science, including basic, translational, and clinical research. See how the AACR grants program has contributed to the AACR's mission.
A growing share of US adult smokers – Hispanic/Latino adults – have been found to be less likely to receive advice to quit and use proven cessation treatments than non-Hispanic white adults. 2021 AACR-Genentech Cancer Disparities Fellow Francisco Cartujano, MD, seeks to address tobacco-related disparities in Latinos by promoting smoking cessation and physical activity using a mobile intervention.
Triple negative breast cancer (TNBC) is an aggressive cancer with high rates of p53 inactivation and lower survival rates than other breast cancer types due to increased metastasis and relapse (1). Owing to the frequent inactivation of p53, compounds that inhibit p53 from binding to its negative regulator, MDM2, are ineffective in TNBC. In a recent study published in Cancer Discovery, Dr. Eischen and her colleagues used an MDM2-targeted PROteolysis TArgeting Chimera (PROTAC) to reveal the requirement for MDM2 in p53 inactivated TNBC and identify a new therapeutic target for the disease.
Many fellowship programs offer protected research time for clinical fellows to participate in laboratory and clinic-based research as well as their medical training and patient care. This research experience allows clinical fellows to keep abreast of recent medical advancements...
Please join us for an interactive session taking place Monday, April 17th, at the AACR Annual Meeting 2023. The Meet the Research Grant Reviewers session, will give you an opportunity to ask AACR grant reviewers, Dr. DeGregori and Dr. Iacobuzio-Donahue, any questions you may have. We offer you a sneak peak of what you can learn from attending the session here!
Between April 14 – 19, the 2023 AACR Annual Meeting will welcome the best cancer scientists from all over the world to the Orange County Convention Center, Orlando, Florida. We are excited to announce the AACR grantees selected to present their work in oral and poster presentations. We are extremely proud and excited to hear of the progress they have made with support from the AACR and its funding partners!
As we set our eyes on the 2023 AACR Annual Meeting, we kick off our celebration of 30 years of impact of the AACR Research Grants Program, by featuring the first grantee -- 1993 AACR-Gertrude B. Elion Cancer Research Award Recipient Benjamin G. Neel, MD, PhD.
Metastatic prostate cancer (PCa) remains a leading cause of death in men worldwide (1). Although effective treatments exist, therapy resistance in PCa is common. Dr. Rodriguez-Bravo and her research team recently uncovered high chromosomal instability (CIN) and increased mitotic...
Head and neck cancer (HNC), describing cancers of the oral cavity, throat, nose, and sinuses, is the sixth most common cancer worldwide accounting for 300,000 cancer deaths each year. Epidemiological data has shown disparities between HNC screening, detection, treatment,...
Dedicated to accelerating the conquest of cancer, the AACR is a unique organization committed to funding research projects across all cancer sites and researchers at all career levels. In partnership with the Pancreatic Cancer Action Network (PanCAN), a nationwide organization dedicated to pancreatic cancer, the AACR-PanCAN Pathway to Leadership Grant was established in 2010. Running until 2017, the joint program offered $600,000 over five years to facilitate the career transition of pancreatic cancer researchers from postdoctoral/clinical research fellow to independent faculty.
Treatment options for brain cancers, including aggressive glioblastoma, are limited despite the availability of several chemotherapeutic drugs due to the inability of these drugs to cross the blood-brain barrier (BBB). AACR-Novocure grantee Dr. Carsten Hagemann and his team showed that the use of low-intensity alternating electric fields known as Tumor Treating Fields (TTFields), an FDA-approved treatment modality, can facilitate drugs crossing the BBB. Using multiple models, they elucidated the mechanisms driving this action.